Dominik Berthold
Papers
2
Total Citations
40
H-Index
2
About
Dominik Berthold is a leading oncologist whose research focuses on improving outcomes for patients with muscle-invasive bladder cancer through innovative perioperative treatment strategies. His major contributions center on integrating immunotherapy with standard chemotherapy to enhance the efficacy of neoadjuvant and adjuvant regimens. Notably, his work on the SAKK 06/17 phase II trial, which investigates perioperative chemoimmunotherapy with durvalumab in combination with cisplatin and gemcitabine, has garnered significant attention with 32 citations. This study addresses the critical challenge of high relapse rates following standard neoadjuvant chemotherapy and surgery, offering promising preliminary data on the synergistic potential of immune checkpoint inhibitors. Additionally, Berthold has contributed to comparative effectiveness research, such as a multicentre study examining robot-assisted versus open radical cystectomy in patients receiving perioperative chemotherapy, which provides valuable insights from the oncologist’s perspective. His work is highly impactful for clinicians and researchers seeking to refine treatment paradigms for muscle-invasive urothelial carcinoma, bridging the gap between surgical oncology and medical oncology to improve patient survival and quality of life.
Research Focus
Key Achievements
Top Papers
- 1
- 2